Express Delivery
All orders are shipped with Speedy
Cash on delivery
Reliable and convenient payment methods
Proven quality
Peptides Tested at Janoshik Labs
These products are intended solely for scientific and research purposes. They are not medicinal products and should not be interpreted as such. These products are not approved for the diagnosis, treatment, cure, or prevention of any disease.
MOTS-c is a peptide molecule identified by Dr. Pinchas Cohen and a research team from the University of Southern California. It originates from mitochondria—the cellular structures centrally involved in the production and regulation of energy within the cell.
MOTS-c is a relatively new subject of scientific interest and continues to be actively studied to clarify its biological functions more precisely. In published literature, the peptide is regarded as a mitochondrially-encoded signaling molecule associated with metabolic regulation, energy balance, mitochondrial activity, and cellular adaptation to various stressors.
One of the most frequently discussed aspects of MOTS-c is its role in metabolic control. In experimental models, observations have been described regarding improved glucose tolerance, increased insulin sensitivity, and influence on cellular mechanisms involved in energy metabolism and metabolic homeostasis.
In publications related to Cell Metabolism, MOTS-c has been described as a mitochondrial peptide that can activate key metabolic pathways and participate in the regulation of glucose homeostasis. In experimental models, improvements in metabolic control, physical endurance, and cellular response to energetic stress have been observed.
Further research examines MOTS-c as a signaling molecule that can communicate with various cells and tissues. In this context, the peptide is studied in relation to mitochondrial activity, inflammatory processes, cellular adaptation, and mechanisms associated with aging.
Example concentrations for 10 mg / 2 ml solution:
0.3 ml = 1.5 mg
0.4 ml = 2 mg
0.5 ml = 2.5 mg
0.6 ml = 3 mg
Currently, there are not enough large-scale clinical data to allow for a full assessment of the safety profile in humans. In limited observations, mild and transient adverse reactions such as:
Due to the limited volume of human data, no definitive conclusions can be drawn regarding long-term safety, optimal quantities, or efficacy in various conditions.
The information is summarized based on available scientific publications and is for educational purposes only. It should not be used for the diagnosis, treatment, or prevention of diseases.